<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370868">
  <stage>Registered</stage>
  <submitdate>15/08/2016</submitdate>
  <approvaldate>26/08/2016</approvaldate>
  <actrnumber>ACTRN12616001166460</actrnumber>
  <trial_identification>
    <studytitle>A Novel Liver Targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men with Prostate Cancer - A Blinded Randomized Controlled Trial</studytitle>
    <scientifictitle>A Novel Liver Targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men with Prostate Cancer - A Blinded Randomized Controlled Trial</scientifictitle>
    <utrn>U1111-1185-9549</utrn>
    <trialacronym>SADMCAP Trial</trialacronym>
    <secondaryid>nil known
</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <healthcondition>Sarcopenia</healthcondition>
    <healthcondition>Androgen Deprivation Therapy</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>40mg oral testosterone daily for 6 months

Will monitor adherence by patient log and drug packet return</interventions>
    <comparator>Placebo for 6 months - microcellulose</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Measure of lean body mass after 6 months enrolment
Aim for difference between treatment and placebo arms of 1.6kg at 80% power with 0.05 significance
Will assess using DEXA scan</outcome>
      <timepoint>6 months post commencement of intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prostate cancer progression
Assessed by PSA test</outcome>
      <timepoint>6 months post commencement of intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All men with prostate cancer on Androgen Deprivation therapy
 - no time limit regarding diagnosis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>50% increase in PSA or increase in PSA to &gt;4nmol/L above baseline after commencement of intervention
Previous Thyroid Dysfunction
Serious adverse event caused by product
Participants decision to withdrawl
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers</concealment>
    <sequence>Simple randomisation using block design</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Proof of concept analysis
Assuming that treatment maintains LBM over 6 months, a sample size of 25 per group is required to achieve a significance difference 1.6kg LBM at 0.05 significance with 80% power between treatment and placebo. The present study sample size allows for a 10% drop out. </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>8/08/2016</actualstartdate>
    <anticipatedenddate>31/12/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <currentsamplesize>25</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Greenslopes Private Hospital - Greenslopes</hospital>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>4120 - Greenslopes</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Metro South Health and Hospital Service</primarysponsorname>
    <primarysponsoraddress>Princess Alexandra Hospital
199 Ipswich Road, Woolloongabba, QLD 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Prostate Cancer Foundation Australia</fundingname>
      <fundingaddress>PO Box 499
St Leonards NSW 1590
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Prostate Cancer Foundation Australia</sponsorname>
      <sponsoraddress>PO Box 499
St Leonards NSW 1590
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this trial is to evaluate the efficacy of oral testosterone for the prevention and treatment of sarcopenia in men with prostate cancer on Androgen Deprivation Therapy (ADT).

Who is it for?
You may be eligible to participate in this trial if you are aged 18 or over and have been diagnosed with prostate cancer, for which you are undergoing ADT.

Study details
All participants enrolled in this study will be randomly allocated (by chance) to receive either oral testosterone once per day for six months, or to receive an inactive sham tablet once per day for six months. All participants will be reviewed for sarcopenia by assessment of muscle mass with DEXA at six months, and for prostate cancer progression by PSA.

It is hoped that the findings from this trial will provide information on the efficacy of oral testosterone for the prevention of sarcopenia in patients commencing ADT and the reversal of sarcopenia in patients on long term ADT, whilst evaluating whether this treatment has any impact on prostate cancer progression.</summary>
    <trialwebsite>nil</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Metro South HHS Human Research Ethics Committee</ethicname>
      <ethicaddress>Metro South HHS Human Research Ethics Committee
Princess Alexandra Hospital
Ipswich Rd
Wooloongabba
QLD 4102</ethicaddress>
      <ethicapprovaldate>20/04/2016</ethicapprovaldate>
      <hrec>HREC/16/QPAH/105</hrec>
      <ethicsubmitdate>10/02/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/370868-2016_March_15 Ho PICF VERSION 2._KHdoc.doc</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Ken Ho</name>
      <address>c/o Maria Wojciechowski, 
Project Officer &amp; ESO to Professor Ken Ho &amp; Paul DallAlba
Centres for Health Research Metro South Health
Level 7, Translational Research Institute, 37 Kent Street, WOOLLOONGABBA QLD 4102</address>
      <phone>+61 7 34438066</phone>
      <fax />
      <email>ken.ho@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ken Ho</name>
      <address>c/o Maria Wojciechowski, Project Officer &amp; ESO to Professor Ken Ho &amp; Paul DallAlba Centres for Health Research Metro South Health Level 7, Translational Research Institute, 37 Kent Street, WOOLLOONGABBA QLD 4102 a</address>
      <phone>+61 7 34438066 </phone>
      <fax />
      <email>ken.ho@health.qld.gov.au </email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ken Ho</name>
      <address>c/o Maria Wojciechowski, Project Officer &amp; ESO to Professor Ken Ho, Centres for Health Research Metro South Health Level 7, Translational Research Institute, 37 Kent Street, WOOLLOONGABBA QLD 4102 </address>
      <phone>+61 7 34438066 </phone>
      <fax />
      <email>ken.ho@health.qld.gov.au </email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ken Ho</name>
      <address>c/o Maria Wojciechowski, Project Officer &amp; ESO to Professor Ken Ho &amp; Paul DallAlba Centres for Health Research Metro South Health Level 7, Translational Research Institute, 37 Kent Street, WOOLLOONGABBA QLD 4102 </address>
      <phone>+61 7 34438066 </phone>
      <fax />
      <email>ken.ho@health.qld.gov.au </email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>